Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Sixthfin UK Financial Close Management Software Evaluation Criteria Released as Multi-ERP Control, Account Justification and Audit Evidence Enter 2026 Vendor Scorecards

GlobeNewswire
The eleven criteria move close automation platform comparisons in the UK beyond workflow features to multi-entity controls, ERP coverage, account analysis and justification, analytical review, transaction-level drill-down, reporting dashboards, audit evidence and implementation requirements. They are intended to help UK enterprises structure a financial close automation vendor comparison around the reliability of the accounts produced, rather than around feature lists or the length of the close. The eleven criteria move close automation platform comparisons in the UK beyond workflow features to multi-entity controls, ERP coverage, account analysis and justification, analytical review, transaction-level drill-down, reporting dashboards, audit evidence and implementation requirements. They are intended to help UK enterprises structure a financial close automation vendor comparison around the reliability of the accounts produced, rather than around feature lists or the length of the close.
  1. Bronstein, Gewirtz & Grossman LLC Urges Endava plc Investors to Act: Class Action Filed Alleging Investor HarmNew class action for Endava plc (DAVA) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/30/2026
  2. FinanceROSEN, TRUSTED INVESTOR COUNSEL, Encourages Webull Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BULLWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Webull Corporation (NASDAQ: BULL) between April 26, 2025 and October 6, 2026, both dates inclusive (the “Class Period”), of the important December 7, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
  3. Bronstein, Gewirtz & Grossman LLC Urges York Space Systems, Inc. Investors to Act: Class Action Filed Alleging Investor HarmNew class action for York Space (YSS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/30/2026
  4. FinanceROSEN, TRUSTED INVESTOR COUNSEL, Encourages Alphabet Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GOOGL, GOOGWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Alphabet Inc. (NASDAQ: GOOGL, GOOG) between May 19, 2026 and July 16, 2026, inclusive (the “Class Period”), of the important December 1, 2026 lead plaintiff deadline.
  5. FinanceYSS IMPORTANT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages York Space Systems Inc. Investors to Secure Counsel Before Important October 30 Deadline in Securities Class Action – YSSWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of York Space Systems Inc. (NYSE: YSS): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with York Space Systems’ January 2026 initial public offering (“IPO”); and/or (ii) securities between January 29, 2026 and May 11, 2026, both dates inclusive (the “Class Period”), of the important October 30, 2026 lead plaintiff deadline.
  6. FinanceSpyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical data across all three of Spyre’s IBD antibodies—SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23)—which are now being tested as monotherapies and pairwise combinations in the SKYLINE study, as well as new preclinical data demonstrating additive efficacy of these complementary mechanisms.